{"entity":{"id":"2016","kind":"year","name":"2016 in oncology","aka":["2016"],"tldr":"Everything OnCo dates to 2016: 448 entries, 136 papers listed on people's pages, 121 papers, 80 landmarks and 47 trials reported. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"448 dated entries in OnCo fall in 2016: 136 papers listed on people's pages, 121 papers, 80 landmarks, 47 trials reported, 29 approvals, 14 companies founded, 8 regulatory events, 7 technologies, 3 journals founded, 2 laws and regulations and 1 guideline change.\n\nOf those, 8 to the day, 1 to the month and 439 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2015","2017"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2016,"events":[{"group":"approval","date":"2016","precision":"year","title":"Afatinib approved in US","note":"Squamous NSCLC after platinum","from":"afatinib","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Aminolevulinic acid (topical, for photodynamic therapy) approved in US","note":"Mild to moderate actinic keratosis of face and scalp with red-light PDT (Ameluz)","from":"aminolevulinic-acid","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase) approved in EU","note":"Oncaspar centralised 2016; Erwinase and native asparaginases national","from":"asparaginase","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Atezolizumab approved in US","note":"Urothelial carcinoma (later withdrawn); NSCLC","from":"atezolizumab","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Cabozantinib approved in US","note":"Advanced RCC","from":"cabozantinib","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"cobas EGFR Mutation Test v2 approved in US","note":"v2: T790M for osimertinib; plasma testing (first liquid biopsy companion diagnostic)","from":"cobas-egfr-mutation-test","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Crizotinib approved in US","note":"ROS1-positive metastatic NSCLC","from":"crizotinib","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Defibrotide approved in US","note":"Hepatic veno-occlusive disease with renal or pulmonary dysfunction after HSCT, adults and children","from":"defibrotide","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Dexamethasone approved in EU","note":"Multiple myeloma in combination (Neofordex)","from":"dexamethasone","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Eribulin approved in US","note":"Unresectable or metastatic liposarcoma after anthracycline","from":"eribulin","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Everolimus approved in US","note":"Progressive non-functional lung and GI NETs","from":"everolimus","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Fluciclovine F-18 approved in US","note":"PET imaging in men with suspected prostate cancer recurrence based on elevated PSA","from":"fluciclovine-f18","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Gallium-68 DOTATATE (and Cu-64 DOTATATE) approved in US","note":"PET localisation of SSTR-positive neuroendocrine tumours (Ga-68 DOTATATE)","from":"ga68-dotatate","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Granisetron approved in US","note":"Extended-release injection for acute and delayed nausea and vomiting with moderately emetogenic or anthracycline-cyclophosphamide chemotherapy (Sustol)","from":"granisetron","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Ibrutinib approved in US","note":"First-line CLL (RESONATE-2)","from":"ibrutinib","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Ixazomib approved in EU","note":"Same","from":"ixazomib","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Lenvatinib approved in US","note":"Advanced RCC with everolimus after anti-angiogenic therapy","from":"lenvatinib","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Liposomal irinotecan approved in EU","note":"Metastatic pancreatic adenocarcinoma after gemcitabine, with fluorouracil and leucovorin. EMA EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-pegylated-liposomal","from":"liposomal-irinotecan","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Liposomal irinotecan approved in EU","note":"Metastatic adenocarcinoma of the pancreas after gemcitabine-based therapy, with fluorouracil and leucovorin (marketing authorisation 14 October 2016, orphan designation 2011); the...","from":"liposomal-irinotecan","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Melphalan (including hepatic delivery system) approved in US","note":"High-dose conditioning before autologous HSCT in myeloma (Evomela)","from":"melphalan","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) approved in EU","note":"Onivyde 2L after gemcitabine (2016); NALIRIFOX label 2025","from":"nalirifox","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Necitumumab approved in EU","note":"EGFR-expressing locally advanced or metastatic squamous NSCLC with gemcitabine and cisplatin","from":"necitumumab","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Olaratumab approved in US","note":"Soft tissue sarcoma not curable by surgery or radiotherapy, with doxorubicin (accelerated approval). Withdrawn in 2019 after the ANNOUNCE trial","from":"olaratumab","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Ramucirumab approved in England (NICE)","note":"Locally advanced or metastatic non-small-cell lung cancer progressing after platinum-based chemotherapy, with docetaxel: not recommended.","from":"ramucirumab","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Rucaparib approved in US","note":"BRCA-mutated advanced ovarian cancer after ≥2 chemotherapies (later narrowed)","from":"rucaparib","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Trifluridine/tipiracil approved in England (NICE)","note":"Previously treated metastatic colorectal cancer. TA405, published 24 August 2016, recommends it within its marketing authorisation with the patient access scheme discount.","from":"trifluridine-tipiracil","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Trifluridine/tipiracil approved in EU","note":"Metastatic colorectal cancer after available therapies. Lonsurf marketing authorisation issued 25 April 2016.","from":"trifluridine-tipiracil","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"Venetoclax approved in US","note":"CLL with 17p deletion","from":"venetoclax","refs":[]},{"group":"approval","date":"2016","precision":"year","title":"VENTANA PD-L1 (SP142) Assay approved in US","note":"PD-L1 expression to inform atezolizumab treatment in urothelial carcinoma (later NSCLC)","from":"ventana-pd-l1-sp142","refs":[]},{"group":"company","date":"2016","precision":"year","title":"Bain Capital Life Sciences founded","note":"Boston, MA","from":"bain-capital-life-sciences","refs":[]},{"group":"company","date":"2016","precision":"year","title":"CytoReason founded","note":"Tel Aviv","from":"cytoreason","refs":[]},{"group":"company","date":"2016","precision":"year","title":"Harbour BioMed founded","note":"Rotterdam","from":"harbour-biomed","refs":[]},{"group":"company","date":"2016","precision":"year","title":"I-Mab founded","note":"Rockville, Maryland","from":"i-mab","refs":[]},{"group":"company","date":"2016","precision":"year","title":"Ibex Medical Analytics founded","note":"Boston, MA","from":"ibex-medical-analytics","refs":[]},{"group":"company","date":"2016","precision":"year","title":"Iktos founded","note":"Paris","from":"iktos","refs":[]},{"group":"company","date":"2016","precision":"year","title":"intoDNA founded","note":"Krakow, Poland","from":"intodna","refs":[]},{"group":"company","date":"2016","precision":"year","title":"JW Therapeutics founded","note":"Shanghai","from":"jw-therapeutics","refs":[]},{"group":"company","date":"2016","precision":"year","title":"Kheiron Medical Technologies founded","note":"London","from":"kheiron-medical-technologies","refs":[]},{"group":"company","date":"2016","precision":"year","title":"Optellum founded","note":"Oxford","from":"optellum","refs":[]},{"group":"company","date":"2016","precision":"year","title":"Osara Health founded","note":"New York, NY","from":"osara-health","refs":[]},{"group":"company","date":"2016","precision":"year","title":"Radformation founded","note":"New York, NY","from":"radformation","refs":[]},{"group":"company","date":"2016","precision":"year","title":"Salubris Biotherapeutics founded","note":"Gaithersburg, Maryland","from":"salubris-biotherapeutics","refs":[]},{"group":"company","date":"2016","precision":"year","title":"Turbine founded","note":"Budapest","from":"turbine","refs":[]},{"group":"history","date":"2016","precision":"year","title":"2 mm margin standard (SSO-ASTRO-ASCO)","note":"Ductal carcinoma in situ (DCIS)","from":"ductal-carcinoma-in-situ","refs":["lumpectomy"]},{"group":"history","date":"2016","precision":"year","title":"68Ga-DOTATATE PET (Netspot) approved; RADIANT-4 extends everolimus to lung/GI NETs","note":"Neuroendocrine tumours","from":"neuroendocrine","refs":["sstr-pet","radiant-3-4"]},{"group":"history","date":"2016","precision":"year","title":"A resistance map by inhibitor generation","note":"Non-small-cell lung cancer. Across 103 repeat biopsies, each ALK inhibitor is shown to select its own spectrum of resistance mutations, with G1202R rising after second-generation t...","from":"nsclc","refs":["paper-gainor-alk-resistance-mutations-cancer-discov-2016","alk"]},{"group":"history","date":"2016","precision":"year","title":"AALL0232: high-dose methotrexate beats Capizzi methotrexate in high-risk B-ALL","note":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","from":"all-paediatric-high-risk","refs":["methotrexate","leucovorin"]},{"group":"history","date":"2016","precision":"year","title":"AALL1521 opens: ruxolitinib with chemotherapy for CRLF2 and JAK-pathway Ph-like ALL","note":"Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)","from":"all-ph-like","refs":["ruxolitinib"]},{"group":"history","date":"2016","precision":"year","title":"Alliance N0574: radiosurgery alone preserves cognition","note":"Brain metastases (secondary brain tumours). Brown and colleagues (JAMA): cognitive deterioration at three months in 63.5 percent with radiosurgery alone against 91.7 percent with a...","from":"secondary-brain-tumours","refs":["alliance-n0574","radiosurgery-srs"]},{"group":"history","date":"2016","precision":"year","title":"Alliance N0574: radiosurgery alone preserves cognition better than adding whole-brain radiotherapy","note":"HER2-positive breast cancer with brain metastases","from":"her2-positive-breast-brain-metastases","refs":["alliance-n0574"]},{"group":"history","date":"2016","precision":"year","title":"Atezolizumab: first immunotherapy approval in bladder cancer","note":"Muscle-invasive and advanced bladder cancer","from":"muscle-invasive-bladder-cancer","refs":[]},{"group":"history","date":"2016","precision":"year","title":"Atezolizumab: first new bladder cancer drug in 30 years (later withdrawn)","note":"Bladder & urothelial cancer","from":"urothelial","refs":["atezolizumab"]},{"group":"history","date":"2016","precision":"year","title":"Atezolizumab: first new bladder drug in 30 years","note":"Bladder & urothelial cancer","from":"urothelial","refs":[]},{"group":"history","date":"2016","precision":"year","title":"Bailey's four subtypes; NAPOLI-1 gives a second line","note":"Pancreatic ductal adenocarcinoma. 456 tumours, 32 genes, 10 pathways, squamous subtype worst. Liposomal irinotecan with fluorouracil: 6.1 versus 4.2 months after gemcitabine.","from":"pancreatic","refs":["paper-bailey-molecular-subtypes-pancreatic-nature-2016","paper-napoli-1-nanoliposomal-irinotecan-lancet-2016","liposomal-irinotecan"]},{"group":"history","date":"2016","precision":"year","title":"BALLAD adjuvant trial opens","note":"Small intestine cancer (small bowel adenocarcinoma). First randomised trial in resected small bowel adenocarcinoma (NCT02502370).","from":"small-bowel","refs":[]},{"group":"history","date":"2016","precision":"year","title":"Blood after surgery predicts relapse","note":"Colorectal cancer. Circulating tumour DNA after resection of stage II colon cancer gave a recurrence hazard ratio of 18 in 230 patients, the measurement every later trial of residu...","from":"colorectal","refs":["paper-tie-ctdna-minimal-residual-disease-stage-ii-colon-sci-transl-med-2016","paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016","ctdna-mrd-positive","her2-ish-amplified"]},{"group":"history","date":"2016","precision":"year","title":"Cabozantinib approved (METEOR)","note":"Renal cell carcinoma","from":"rcc","refs":["cabozantinib"]},{"group":"history","date":"2016","precision":"year","title":"CheckMate 141: nivolumab after platinum","note":"Recurrent or metastatic head and neck squamous cell carcinoma","from":"recurrent-metastatic-hnscc","refs":["checkmate-141"]},{"group":"history","date":"2016","precision":"year","title":"CHHiP: 60 Gy in 20 fractions non-inferior to 74 Gy in 37","note":"Localised prostate cancer, intermediate risk","from":"prostate-intermediate-risk","refs":["chhip"]},{"group":"history","date":"2016","precision":"year","title":"Crizotinib approved for ROS1-positive lung cancer","note":"ROS1-positive non-small-cell lung cancer","from":"ros1-positive-nsclc","refs":["crizotinib"]},{"group":"history","date":"2016","precision":"year","title":"Divergent clonal evolution from adenocarcinoma shown by sequencing","note":"Neuroendocrine and small-cell prostate cancer","from":"prostate-nepc","refs":[]},{"group":"history","date":"2016","precision":"year","title":"Eribulin approved for liposarcoma after a survival benefit","note":"Liposarcoma","from":"liposarcoma","refs":["eribulin"]},{"group":"history","date":"2016","precision":"year","title":"EURAMOS-1: no benefit from intensifying for poor responders or interferon for good responders","note":"Osteosarcoma","from":"osteosarcoma","refs":[]},{"group":"history","date":"2016","precision":"year","title":"FAST phase 2: claudin 18.2 antibody plus chemotherapy improves survival","note":"Claudin 18.2-positive gastric cancer","from":"gastric-cldn18-2-positive","refs":[]},{"group":"history","date":"2016","precision":"year","title":"First BET inhibitor responses in patients","note":"NUT carcinoma (midline carcinoma with NUTM1 rearrangement). Birabresib (OTX015) and molibresib phase 1 cohorts.","from":"nut-carcinoma","refs":["epigenetic-drugs"]},{"group":"history","date":"2016","precision":"year","title":"GEM20110714: gemcitabine-cisplatin becomes first-line standard for metastatic disease","note":"Recurrent and metastatic nasopharyngeal carcinoma","from":"recurrent-metastatic-nasopharyngeal-carcinoma","refs":["gemcitabine-cisplatin"]},{"group":"history","date":"2016","precision":"year","title":"H3K27me3 loss adopted as a diagnostic marker","note":"Malignant peripheral nerve sheath tumour (MPNST)","from":"malignant-peripheral-nerve-sheath-tumour","refs":[]},{"group":"history","date":"2016","precision":"year","title":"HER2 becomes a colorectal target","note":"Colorectal cancer. HERACLES treated RAS wild-type patients with HER2 amplification using trastuzumab and lapatinib and got responses in 8 of 27.","from":"colorectal","refs":["paper-tie-ctdna-minimal-residual-disease-stage-ii-colon-sci-transl-med-2016","ctdna","mrd"]},{"group":"history","date":"2016","precision":"year","title":"HERACLES: trastuzumab plus lapatinib produces responses in 30 percent","note":"HER2-amplified colorectal cancer","from":"her2-amplified-colorectal","refs":["trastuzumab"]},{"group":"history","date":"2016","precision":"year","title":"Hereditary alpha-tryptasaemia described, explaining raised tryptase in some patients","note":"Indolent and smouldering systemic mastocytosis","from":"indolent-systemic-mastocytosis","refs":[]},{"group":"history","date":"2016","precision":"year","title":"HPV-independent vs HPV-associated pathways defined (WHO 2020 adopts)","note":"Vulvar cancer","from":"vulvar","refs":[]},{"group":"history","date":"2016","precision":"year","title":"Hypothalamus-sparing surgery recommended","note":"Craniopharyngioma. KRANIOPHARYNGEOM 2007 shows radical resection with hypothalamic injury worsens quality of life without improving control.","from":"craniopharyngioma","refs":[]},{"group":"history","date":"2016","precision":"year","title":"IELSG32: MATRix induction","note":"Primary CNS lymphoma. Adding rituximab and thiotepa to methotrexate-cytarabine improves response and survival.","from":"primary-cns-lymphoma","refs":["rituximab","methotrexate"]},{"group":"history","date":"2016","precision":"year","title":"Inherited DNA repair faults turn out to be common and unpredictable","note":"Prostate cancer. Pritchard found presumed deleterious germline DNA repair mutations in 11.8 percent of 692 men with metastatic prostate cancer, BRCA2 in 5.3 percent, with no relati...","from":"prostate","refs":["paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016"]},{"group":"history","date":"2016","precision":"year","title":"INO-VATE: CD22 ADC beats chemotherapy in relapse","note":"Acute lymphoblastic leukaemia. CR/CRi 81% vs 29%; approval 2017.","from":"all-leukemia","refs":["inotuzumab-ozogamicin","ino-vate"]},{"group":"history","date":"2016","precision":"year","title":"Intensity-modulated radiotherapy becomes standard after RTOG 0529 reduces toxicity","note":"Localised anal squamous cell carcinoma (stage I to III)","from":"localised-anal-cancer","refs":["imrt-igrt"]},{"group":"history","date":"2016","precision":"year","title":"Japan recommends endoscopic over radiographic screening; KLASS-01 supports laparoscopic gastrectomy","note":"Early gastric cancer","from":"early-gastric-cancer","refs":[]},{"group":"history","date":"2016","precision":"year","title":"KEYNOTE-024: pembrolizumab alone beats chemotherapy in PD-L1-high disease; first-line approval","note":"PD-L1-high non-small-cell lung cancer without a driver mutation","from":"pdl1-high-nsclc","refs":["keynote-024-189","pembrolizumab","martin-reck","paper-keynote-024-nejm-2016"]},{"group":"history","date":"2016","precision":"year","title":"LAP07: chemoradiation after induction gemcitabine controls local growth but does not lengthen survival","note":"Locally advanced unresectable pancreatic ductal adenocarcinoma","from":"locally-advanced-pdac","refs":["chemoradiation","gemcitabine"]},{"group":"history","date":"2016","precision":"year","title":"MAPS: bevacizumab adds ~3 months","note":"Mesothelioma","from":"mesothelioma","refs":["maps"]},{"group":"history","date":"2016","precision":"year","title":"Midostaurin in advanced SM","note":"Systemic mastocytosis. Gotlib and colleagues (NEJM 2016); FDA approval April 2017.","from":"systemic-mastocytosis","refs":["midostaurin"]},{"group":"history","date":"2016","precision":"year","title":"Midostaurin phase 2: 60 percent response rate in advanced systemic mastocytosis","note":"Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)","from":"advanced-systemic-mastocytosis","refs":["midostaurin"]},{"group":"history","date":"2016","precision":"year","title":"MINDACT: genomic low-risk women can skip chemotherapy","note":"High-risk early HR-positive breast cancer","from":"hr-positive-early-high-risk","refs":["mindact","mammaprint"]},{"group":"history","date":"2016","precision":"year","title":"Muraki and colleagues report a more protracted course in 38 resected cases","note":"Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells","from":"pancreatic-undifferentiated-carcinoma-ogc","refs":["tumour-grade"]},{"group":"history","date":"2016","precision":"year","title":"Nivolumab (CheckMate 141) and pembrolizumab approved after platinum","note":"Head and neck squamous cell carcinoma","from":"head-and-neck","refs":["checkmate-141","nivolumab","pembrolizumab"]},{"group":"history","date":"2016","precision":"year","title":"Nivolumab approved after CheckMate 205","note":"Relapsed and refractory classical Hodgkin lymphoma","from":"relapsed-refractory-hodgkin-lymphoma","refs":["nivolumab","checkmate-205"]},{"group":"history","date":"2016","precision":"year","title":"NPM1 transcript MRD predicts relapse after chemotherapy","note":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","from":"aml-npm1-kmt2a","refs":["mrd"]},{"group":"history","date":"2016","precision":"year","title":"PD-1 approved second line","note":"Head and neck squamous cell carcinoma","from":"head-and-neck","refs":[]},{"group":"history","date":"2016","precision":"year","title":"Pembrolizumab first-line phase 2 (KEYNOTE-017, NEJM)","note":"Merkel cell carcinoma","from":"merkel-cell-carcinoma","refs":["pembrolizumab"]},{"group":"history","date":"2016","precision":"year","title":"ProtecT validates active surveillance","note":"Prostate cancer","from":"prostate","refs":["protect","active-surveillance"]},{"group":"history","date":"2016","precision":"year","title":"ProtecT: ten-year mortality about 1 percent whether monitored or treated","note":"Localised prostate cancer, very low and low risk","from":"prostate-low-risk","refs":["protect"]},{"group":"history","date":"2016","precision":"year","title":"PSOGI classification of appendiceal mucinous neoplasms and PMP","note":"Appendiceal cancer and pseudomyxoma peritonei","from":"appendiceal","refs":[]},{"group":"history","date":"2016","precision":"year","title":"PSOGI consensus classification of appendiceal mucinous neoplasms and pseudomyxoma peritonei","note":"Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei","from":"low-grade-appendiceal-mucinous-neoplasm","refs":[]},{"group":"history","date":"2016","precision":"year","title":"PSOGI consensus defines mucinous adenocarcinoma and signet ring cell carcinoma grades","note":"Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)","from":"appendiceal-adenocarcinoma","refs":[]},{"group":"history","date":"2016","precision":"year","title":"Punctuated evolution: two-thirds of pancreatic cancer genomes shaped by mitotic catastrophe","note":"Pancreatic ductal adenocarcinoma. Notta's whole genomes show chromothripsis and polyploidy, not stepwise mutation, in two-thirds of tumours, knocking out several drivers at once; B...","from":"pancreatic","refs":["paper-notta-punctuated-evolution-pancreatic-nature-2016","kdm6a"]},{"group":"history","date":"2016","precision":"year","title":"QUARTZ: no quality-adjusted survival gain from whole-brain radiotherapy in poor-prognosis lung cancer","note":"Brain metastases (secondary brain tumours)","from":"secondary-brain-tumours","refs":["quartz","wbrt"]},{"group":"history","date":"2016","precision":"year","title":"RADIANT-4 extends everolimus to gut and lung tumours; gallium-68 DOTATATE PET approved","note":"Small intestinal neuroendocrine tumours","from":"small-intestinal-net","refs":["radiant-3-4","everolimus","sstr-pet","ga68-dotatate"]},{"group":"history","date":"2016","precision":"year","title":"RADIANT-4: everolimus approved for lung neuroendocrine tumours","note":"Lung neuroendocrine tumours (typical and atypical carcinoid)","from":"lung-net","refs":["radiant-3-4","everolimus"]},{"group":"history","date":"2016","precision":"year","title":"RATHL: bleomycin dropped after negative interim PET; nivolumab approved for relapse (CheckMate 205)","note":"Hodgkin lymphoma","from":"hodgkin-lymphoma","refs":["rathl","checkmate-205","nivolumab"]},{"group":"history","date":"2016","precision":"year","title":"RATHL: PET-guided omission of bleomycin","note":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","from":"advanced-stage-classical-hodgkin-lymphoma","refs":["rathl","pet-adapted-therapy"]},{"group":"history","date":"2016","precision":"year","title":"Revised Histiocyte Society classification","note":"Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms. L, C, R, M and H groups (Emile et al., Blood 2016).","from":"histiocytoses","refs":[]},{"group":"history","date":"2016","precision":"year","title":"Revised histiocytosis classification creates the R group for Rosai-Dorfman disease","note":"Rosai-Dorfman-Destombes disease","from":"rosai-dorfman-disease","refs":[]},{"group":"history","date":"2016","precision":"year","title":"Revised histiocytosis classification places Erdheim-Chester and Langerhans cell histiocytosis together in the L group","note":"Erdheim-Chester disease","from":"erdheim-chester-disease","refs":[]},{"group":"history","date":"2016","precision":"year","title":"RTOG 9802: radiotherapy plus PCV doubles survival in high-risk low-grade glioma","note":"Astrocytoma, IDH-mutant (grades 2 to 4). Buckner and colleagues (NEJM) report median overall survival of 13.3 years against 7.8 years with radiotherapy alone.","from":"idh-mutant-astrocytoma","refs":["procarbazine","lomustine","vincristine"]},{"group":"history","date":"2016","precision":"year","title":"RTOG 9802: radiotherapy plus PCV for high-risk grade 2 glioma, including oligodendroglioma","note":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","from":"oligodendroglioma","refs":["procarbazine","lomustine","vincristine"]},{"group":"history","date":"2016","precision":"year","title":"Sirolimus activity reported in progressive epithelioid haemangioendothelioma","note":"Epithelioid haemangioendothelioma","from":"epithelioid-haemangioendothelioma","refs":["mtor"]},{"group":"history","date":"2016","precision":"year","title":"STAMPEDE confirms docetaxel at first diagnosis","note":"Metastatic hormone-sensitive prostate cancer","from":"prostate-mhspc","refs":["stampede"]},{"group":"history","date":"2016","precision":"year","title":"TCGA/ENSAT genomic classification of ACC (Zheng, Cancer Cell)","note":"Adrenocortical carcinoma","from":"adrenocortical","refs":[]},{"group":"history","date":"2016","precision":"year","title":"The lineage change is mapped, and it is epigenetic before it is genetic","note":"Prostate cancer. Methylation separates neuroendocrine from castration-resistant adenocarcinoma far more sharply than mutations do, in a pattern fitting divergent clonal evolution f...","from":"prostate","refs":["paper-beltran-nepc-divergent-evolution-nat-med-2016"]},{"group":"history","date":"2016","precision":"year","title":"Three molecular subgroups defined","note":"Atypical teratoid/rhabdoid tumour (ATRT). Johann and Torchia (Cancer Cell) describe ATRT-TYR, ATRT-SHH and ATRT-MYC by methylation and expression.","from":"atrt","refs":["methylation-profiling"]},{"group":"history","date":"2016","precision":"year","title":"TNBCtype-4 and the HRD score threshold","note":"Triple-negative breast cancer (TNBC). Lehmann refines the subtypes to four (BL1 35%, BL2 22%, M 25%, LAR 16%) with pCR 41% versus 18% versus 29%; Telli sets HRD score 42 in neoadju...","from":"tnbc","refs":["paper-lehmann-tnbctype-4-refinement-plos-one-2016","paper-telli-hrd-score-platinum-tnbc-ccr-2016"]},{"group":"history","date":"2016","precision":"year","title":"Venetoclax approved","note":"Chronic lymphocytic leukaemia","from":"cll","refs":["venetoclax"]},{"group":"history","date":"2016","precision":"year","title":"Venetoclax approved (del(17p)); ibrutinib first line","note":"Chronic lymphocytic leukaemia. First BCL-2 inhibitor; RESONATE-2 moves ibrutinib to untreated CLL.","from":"cll","refs":["venetoclax","ibrutinib"]},{"group":"history","date":"2016","precision":"year","title":"Venetoclax approved for relapsed del(17p) CLL","note":"Relapsed or refractory chronic lymphocytic leukaemia","from":"cll-relapsed","refs":["venetoclax"]},{"group":"history","date":"2016","precision":"year","title":"WHO 2016 classification makes IDH status part of the diagnosis","note":"Astrocytoma, IDH-mutant (grades 2 to 4)","from":"idh-mutant-astrocytoma","refs":["idh"]},{"group":"history","date":"2016","precision":"year","title":"WHO 2016 defines oligodendroglioma by IDH mutation and 1p/19q codeletion","note":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","from":"oligodendroglioma","refs":[]},{"group":"history","date":"2016","precision":"year","title":"WHO 2016 integrates molecular markers; ACT IV vaccine fails","note":"Glioma & glioblastoma","from":"glioblastoma","refs":["act-iv","rindopepimut"]},{"group":"history","date":"2016","precision":"year","title":"WHO adopts molecular groups; ACNS1422 opens with 18 Gy craniospinal radiotherapy for WNT tumours","note":"WNT-activated medulloblastoma","from":"medulloblastoma-wnt","refs":["childrens-oncology-group"]},{"group":"history","date":"2016","precision":"year","title":"WHO classification adds molecular markers","note":"Brain and spinal cord tumours (all types). IDH mutation, 1p/19q codeletion and H3 K27M began to define brain tumour types alongside microscopy; extended in 2021.","from":"brain-tumours","refs":[]},{"group":"history","date":"2016","precision":"year","title":"WHO defines AML with myelodysplasia-related changes as its own group","note":"Secondary and therapy-related acute myeloid leukaemia","from":"aml-secondary","refs":[]},{"group":"history","date":"2016","precision":"year","title":"WHO integrates molecular groups into classification","note":"Medulloblastoma","from":"medulloblastoma","refs":[]},{"group":"history","date":"2016","precision":"year","title":"WHO recognises diffuse midline glioma, H3 K27M-mutant","note":"Diffuse midline glioma, H3 K27-altered (including DIPG). First histone-defined tumour entity.","from":"dipg-dmg","refs":[]},{"group":"history","date":"2016","precision":"year","title":"WHO separates prefibrotic myelofibrosis from ET","note":"Essential thrombocythaemia (ET). Marrow histology now distinguishes true ET from early myelofibrosis, which carries a worse outlook.","from":"essential-thrombocythaemia","refs":[]},{"group":"journal","date":"2016","precision":"year","title":"Blood Advances founded","note":"American Society of Hematology","from":"blood-advances","refs":[]},{"group":"journal","date":"2016","precision":"year","title":"Cancer treatment and research communications founded","note":"Elsevier","from":"cancer-treatment-and-research-communications","refs":[]},{"group":"journal","date":"2016","precision":"year","title":"ESMO Open founded","note":"Elsevier","from":"esmo-open","refs":[]},{"group":"law","date":"2016","precision":"year","title":"21st Century Cures Act","note":"United States, statute.","from":"21st-century-cures-act","refs":[]},{"group":"law","date":"2016","precision":"year","title":"GDPR and health data (Regulation (EU) 2016/679)","note":"European Union, regulation.","from":"gdpr","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer","note":"Haugen BR, Alexander EK, Bible KC, et al. Thyroid.","from":"paper-ata-2015-thyroid-nodules-dtc-haugen-thyroid-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere...","note":"Gianni L, Pienkowski T, Im YH, et al. The Lancet Oncology.","from":"paper-neosphere-lancet-oncol-2016-update","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer","note":"Cardoso F, van't Veer LJ, Bogaerts J, et al. New England Journal of Medicine.","from":"paper-cardoso-n-engl-j-med","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns","note":"Notta F, Chan-Seng-Yue M, Lemire M, et al. Nature.","from":"paper-notta-punctuated-evolution-pancreatic-nature-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for insomnia (CBT-I) in cancer survivors","note":"Johnson JA, Rash JA, Campbell TS, et al. Sleep medicine reviews.","from":"paper-johnson-sleep-med-rev","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"AALL0232: dexamethasone and high-dose methotrexate improve outcome in high-risk B-cell acute lymphoblastic leukaemia in children and young adults","note":"Larsen EC, Devidas M, Chen S, et al. Journal of Clinical Oncology.","from":"paper-aall0232-larsen-jco-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia","note":"Byrd JC, Harrington B, O'Brien S, et al. New England Journal of Medicine.","from":"paper-acalabrutinib-cll-n-engl-j-med-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multia...","note":"James ND, Sydes MR, Clarke NW, et al. The Lancet.","from":"paper-stampede-lancet-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Alliance N0574: radiosurgery alone versus radiosurgery plus whole-brain radiotherapy for one to three brain metastases","note":"Brown PD, Jaeckle K, Ballman KV, et al. JAMA.","from":"paper-alliance-n0574-brown-jama-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","note":"Temel JS, Abernethy AP, Currow DC, et al. The Lancet Oncology.","from":"paper-romana-1-2-lancet-oncol-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"ASPEN: everolimus versus sunitinib in metastatic non-clear cell renal cell carcinoma","note":"Armstrong AJ, Halabi S, Eisen T, et al. The Lancet Oncology.","from":"paper-aspen-armstrong-lancet-oncol-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis","note":"Brown TJ, Brennan MC, Li M, et al. JAMA Oncology.","from":"paper-brown-jama-oncol","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled...","note":"Fehrenbacher L, Spira A, Ballinger M, et al. The Lancet.","from":"paper-keunchil-park-lancet-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","note":"Kaufman HL, Russell J, Hamid O, et al. The Lancet Oncology.","from":"paper-javelin-merkel-200-lancet-oncol-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Biliary cancer: utility of next-generation sequencing for clinical management","note":"Javle M, Bekaii-Saab T, Jain A, et al. Cancer.","from":"paper-javle-biliary-ngs-cancer-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study","note":"Villani A, Shore A, Wasserman JD, et al. The Lancet Oncology.","from":"paper-villani-lancet-oncol","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"BMT CTN 0803/AMC 071: autologous haematopoietic cell transplantation for HIV-related lymphoma","note":"Alvarnas JC, Le Rademacher J, Wang Y, et al. Blood.","from":"paper-bmt-ctn-0803-autologous-transplant-hiv-lymphoma-alvarnas-blood-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth facto...","note":"Ogitani Y, Hagihara K, Oitate M, et al. Cancer science.","from":"paper-ogitani-cancer-sci","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Carcinogenicity of drinking coffee, mate, and very hot beverages","note":"Loomis D, Guyton KZ, Grosse Y, et al. The Lancet Oncology.","from":"paper-loomis-lancet-oncol","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer","note":"Chen Q, Boire A, Jin X, et al. Nature.","from":"paper-chen-nature-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","note":"Turtle CJ, Hanafi LA, Berger C, et al. Journal of Clinical Investigation.","from":"paper-cd19-all-leukemia-j-clin-invest-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"CheckMate 141: nivolumab for recurrent head and neck squamous cell carcinoma after platinum","note":"Ferris RL, Blumenschein G, Fayette J, et al. New England Journal of Medicine.","from":"paper-checkmate-141-ferris-nejm-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Chen 2016: Cancer statistics in China, 2015","note":"Chen W, Zheng R, Baade PD, et al. CA: A Cancer Journal for Clinicians.","from":"paper-chen-cancer-statistics-china-2015-cacancer-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"CHHiP: conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer","note":"Dearnaley D, Syndikus I, Mossop H, et al. The Lancet Oncology.","from":"paper-chhip-lancet-oncol-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","note":"Tie J, Wang Y, Tomasetti C, et al. Science Translational Medicine.","from":"paper-tie-ctdna-minimal-residual-disease-stage-ii-colon-sci-transl-med-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","note":"Ascierto PA, McArthur GA, Dréno B, et al. The Lancet Oncology.","from":"paper-cobrim-lancet-oncol-2016-update","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Combined tumour suppressor defects characterise clinically defined aggressive variant prostate cancers","note":"Aparicio AM, Shen L, Tapia ELN, et al. Clinical Cancer Research.","from":"paper-aparicio-aggressive-variant-prostate-tumour-suppressors-ccr-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-la...","note":"Marina NM, Smeland S, Bielack SS, et al. The Lancet Oncology.","from":"paper-marina-lancet-oncol","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Comprehensive molecular characterisation of papillary renal cell carcinoma (The Cancer Genome Atlas)","note":"Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, et al. New England Journal of Medicine.","from":"paper-tcga-papillary-rcc-nejm-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","note":"Buchbinder EI, Desai A. American journal of clinical oncology.","from":"paper-pd-1-nsclc-am-j-clin-oncol-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Dabrafenib plus trametinib in previously treated BRAF V600E-mutant metastatic non-small-cell lung cancer","note":"Planchard D, Besse B, Groen HJM, et al. The Lancet Oncology.","from":"paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","note":"Dimopoulos MA, Oriol A, Nahi H, et al. New England Journal of Medicine.","from":"paper-lenalidomide-multiple-myeloma-n-engl-j-med-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","note":"Campbell JD, Alexandrov A, Kim J, et al. Nature Genetics.","from":"paper-campbell-pan-lung-somatic-alterations-nat-genet-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","note":"Beltran H, Prandi D, Mosquera JM, et al. Nature Medicine.","from":"paper-beltran-nepc-divergent-evolution-nat-med-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","note":"Ogitani Y, Aida T, Hagihara K, et al. Clinical Cancer Research.","from":"paper-ogitani-clin-cancer-res","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES)","note":"Sartore-Bianchi A, Trusolino L, Martino C, et al. The Lancet Oncology.","from":"paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","note":"Gotlib J, Kluin-Nelemans HC, George TI, et al. New England Journal of Medicine.","from":"paper-gotlib-midostaurin-advanced-systemic-mastocytosis-nejm-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Epigenetic Determinants of Cancer","note":"Baylin SB, Jones PA. Cold Spring Harbor perspectives in biology.","from":"paper-baylin-cold-spring-harb-perspect-biol","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Epigenetic modulators, modifiers and mediators in cancer aetiology and progression","note":"Feinberg AP, Koldobskiy MA, Göndör A. Nature reviews. Genetics.","from":"paper-feinberg-nat-rev-genet","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Eribulin versus dacarbazine in previously treated advanced liposarcoma or leiomyosarcoma","note":"Schöffski P, Chawla S, Maki RG, et al. The Lancet.","from":"paper-eribulin-liposarcoma-schoffski-lancet-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer","note":"Ramsey SD, Bansal A, Fedorenko CR, et al. Journal of Clinical Oncology.","from":"paper-ramsey-j-clin-oncol","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"From Krebs to clinic: glutamine metabolism to cancer therapy","note":"Altman BJ, Stine ZE, Dang CV. Nature Reviews Cancer.","from":"paper-altman-nat-rev-cancer","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"From melanocytes to melanomas","note":"Shain AH, Bastian BC. Nature Reviews Cancer.","from":"paper-shain-nat-rev-cancer","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Ganoderma lucidum (Reishi mushroom) for cancer treatment","note":"Jin X, Ruiz Beguerie J, Sze DM, et al. The Cochrane database of systematic reviews.","from":"paper-jin-cochrane-database-syst-rev","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma","note":"Zhang L, Huang Y, Hong S, et al. The Lancet.","from":"paper-zhang-gemcitabine-cisplatin-vs-fluorouracil-cisplatin-rm-npc-lancet-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Genomic analyses identify molecular subtypes of pancreatic cancer","note":"Bailey P, Chang DK, Nones K, et al. Nature.","from":"paper-bailey-molecular-subtypes-pancreatic-nature-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma","note":"Bonilla X, Parmentier L, King B, et al. Nature Genetics.","from":"paper-bonilla-nat-genet","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Genomic correlates of immune-cell infiltrates in colorectal carcinoma","note":"Giannakis M, Mu XJ, Shukla SA, et al. Cell Reports.","from":"paper-giannakis-genomic-correlates-immune-colorectal-cell-rep-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOL...","note":"Richman SD, Southward K, Chambers P, et al. Journal of Pathology.","from":"paper-richman-her2-amplification-quasar-focus-piccolo-j-pathol-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","note":"Telli ML, Timms KM, Reid J, et al. Clinical Cancer Research.","from":"paper-telli-hrd-score-platinum-tnbc-ccr-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Hyperbaric oxygen therapy for late radiation tissue injury","note":"Bennett MH, Feldmeier J, Hampson NB, et al. The Cochrane database of systematic reviews.","from":"paper-bennett-cochrane-database-syst-rev","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"IARC verdict: excess body fat causes 13 cancers","note":"Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K (IARC Handbook Working Group). New England Journal of Medicine.","from":"paper-body-fatness-iarc-nejm-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"IELSG32 first randomisation: the MATRix regimen (methotrexate, cytarabine, thiotepa, rituximab) in primary CNS lymphoma","note":"Ferreri AJ, Cwynarski K, Pulczynski E, et al. The Lancet Haematology.","from":"paper-ielsg32-matrix-induction-ferreri-lancet-haematol-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"IFM 2006 prospective trial: bortezomib-based induction and transplantation for primary plasma cell leukaemia","note":"Royer B, Minvielle S, Diouf M, et al. Journal of Clinical Oncology.","from":"paper-royer-plasma-cell-leukaemia-ifm-jco-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","note":"Sankaranarayanan R, Prabhu PR, Pawlita M, et al. The Lancet Oncology.","from":"paper-sankaranarayanan-lancet-oncol","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","note":"Pritchard CC, Mateo J, Walsh MF, et al. New England Journal of Medicine.","from":"paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL","note":"Kantarjian HM, DeAngelo DJ, Stelljes M, et al. New England Journal of Medicine.","from":"paper-ino-vate-inotuzumab-all-nejm-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Integrative analyses of colorectal cancer show Immunoscore is a stronger predictor of patient survival than microsatellite instability","note":"Mlecnik B, Bindea G, Angell HK, et al. Immunity.","from":"paper-mlecnik-immunoscore-msi-colorectal-immunity-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","note":"Kumar S, Paiva B, Anderson KC, et al. The Lancet Oncology.","from":"paper-kumar-lancet-oncol","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"KEYNOTE-010 (Herbst 2016): pembrolizumab versus docetaxel in previously treated PD-L1-positive lung cancer","note":"Herbst RS, Baas P, Kim DW, et al. The Lancet.","from":"paper-keynote-010-lancet-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"KEYNOTE-024: pembrolizumab alone beats chemotherapy in PD-L1-high lung cancer","note":"Reck M, Rodríguez-Abreu D, Robinson AG, et al. New England Journal of Medicine.","from":"paper-keynote-024-nejm-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma","note":"Bournet B, Muscari F, Buscail C, et al. Clinical and Translational Gastroenterology.","from":"paper-bournet-kras-g12d-prognosis-pancreatic-ctg-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"LAP07: chemoradiotherapy versus continued chemotherapy for locally advanced pancreatic cancer controlled after four months of gemcitabine","note":"Hammel P, Huguet F, van Laethem JL, et al. JAMA.","from":"paper-lap07-chemoradiotherapy-locally-advanced-pancreatic-jama-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","note":"Paice JA, Portenoy R, Lacchetti C, et al. Journal of Clinical Oncology.","from":"paper-paice-j-clin-oncol","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Massage with or without aromatherapy for symptom relief in people with cancer","note":"Shin ES, Seo KH, Lee SH, et al. The Cochrane database of systematic reviews.","from":"paper-shin-cochrane-database-syst-rev","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time?","note":"Hassan R, Thomas A, Alewine C, et al. Journal of Clinical Oncology.","from":"paper-mesothelin-mesothelioma-j-clin-oncol-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors","note":"Morello A, Sadelain M, Adusumilli PS. Cancer Discovery.","from":"paper-mesothelin-mesothelioma-cancer-discov-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression","note":"Awad MM, Oxnard GR, Jackman DM, et al. Journal of Clinical Oncology.","from":"paper-awad-met-exon-14-mutations-lung-jco-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Metastatic colonization by circulating tumour cells","note":"Massagué J, Obenauf AC. Nature.","from":"paper-massague-nature","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-D...","note":"Gebhart G, Lamberts LE, Wimana Z, et al. Annals of Oncology.","from":"paper-gebhart-ann-oncol","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Molecular measurable residual disease in NPM1-mutated acute myeloid leukaemia (UK NCRI AML17)","note":"Ivey A, Hills RK, Simpson MA, et al. New England Journal of Medicine.","from":"paper-ivey-npm1-mrd-nejm-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","note":"Gainor JF, Dardaei L, Yoda S, et al. Cancer Discovery.","from":"paper-gainor-alk-resistance-mutations-cancer-discov-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Mutational signatures associated with tobacco smoking in human cancer","note":"Alexandrov LB, Ju YS, Haase K, et al. Science.","from":"paper-alexandrov-tobacco-smoking-mutational-signatures-science-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","note":"Zaretsky JM, Garcia-Diaz A, Shin DS, et al. New England Journal of Medicine.","from":"paper-zaretsky-n-engl-j-med","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rando...","note":"Wang-Gillam A, Li CP, Bodoky G, et al. The Lancet.","from":"paper-napoli-1-nanoliposomal-irinotecan-lancet-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs","note":"Sturm D, Orr BA, Toprak UH, et al. Cell.","from":"paper-jacques-grill-cell-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","note":"Mirza MR, Monk BJ, Herrstedt J, et al. New England Journal of Medicine.","from":"paper-niraparib-ovarian-n-engl-j-med-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, singl...","note":"Younes A, Santoro A, Shipp M, et al. The Lancet Oncology.","from":"paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"NK cells and cancer: you can teach innate cells new tricks","note":"Morvan MG, Lanier LL. Nature Reviews Cancer.","from":"paper-morvan-nat-rev-cancer","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting","note":"Navari RM, Qin R, Ruddy KJ, et al. New England Journal of Medicine.","from":"paper-navari-n-engl-j-med","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial","note":"Tap WD, Jones RL, Van Tine BA, et al. The Lancet.","from":"paper-robin-jones-lancet-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Palbociclib and Letrozole in Advanced Breast Cancer","note":"Finn RS, Martin M, Rugo HS, et al. New England Journal of Medicine.","from":"paper-paloma-2-n-engl-j-med-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Pancreatic cancer","note":"Kleeff J, Korc M, Apte M, et al. Nature reviews. Disease primers.","from":"paper-kleeff-nat-rev-dis-primers","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma","note":"Nghiem PT, Bhatia S, Lipson EJ, et al. New England Journal of Medicine.","from":"paper-keynote-017-n-engl-j-med-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"PD-L1 expression in human cancers and its association with clinical outcomes","note":"Wang X, Teng F, Kong L, et al. OncoTargets and therapy.","from":"paper-pd-l1-urothelial-onco-targets-ther-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma","note":"Viardot A, Goebeler ME, Hess G, et al. Blood.","from":"paper-viardot-blood","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","note":"Richardson PG, Riches ML, Kernan NA, et al. Blood.","from":"paper-defibrotide-2005-01-blood-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients","note":"Sawada Y, Yoshikawa T, Ofuji K, et al. Oncoimmunology.","from":"paper-gpc3-hcc-oncoimmunology-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Phyllodes tumours of the breast: a consensus review","note":"Tan BY, Acs G, Apple SK, et al. Histopathology.","from":"paper-tan-phyllodes-consensus-histopathology-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Prolonged Nightly Fasting and Breast Cancer Prognosis","note":"Marinac CR, Nelson SH, Breen CI, et al. JAMA Oncology.","from":"paper-marinac-jama-oncol","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"ProtecT: 10-year outcomes after monitoring, surgery or radiotherapy for localised prostate cancer","note":"Hamdy FC, Donovan JL, Lane JA, et al. New England Journal of Medicine.","from":"paper-protect-nejm-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"PSOGI consensus for classification and pathological reporting of pseudomyxoma peritonei and associated appendiceal neoplasia","note":"Carr NJ, Cecil TD, Mohamed F, et al. American Journal of Surgical Pathology.","from":"paper-psogi-pseudomyxoma-appendiceal-classification-am-j-surg-pathol-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"QUARTZ: whole-brain radiotherapy versus supportive care alone for brain metastases from non-small-cell lung cancer","note":"Mulvenna P, Nankivell M, Barton R, et al. The Lancet.","from":"paper-quartz-lancet-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"RADIANT-4: everolimus for advanced non-functional neuroendocrine tumours of the lung or gastrointestinal tract","note":"Yao JC, Fazio N, Singh S, et al. The Lancet.","from":"paper-radiant-4-everolimus-lancet-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"RATHL: adapted treatment guided by interim PET-CT in advanced Hodgkin lymphoma","note":"Johnson P, Federico M, Kirkwood A, et al. New England Journal of Medicine.","from":"paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer","note":"Armstrong GT, Chen Y, Yasui Y, et al. New England Journal of Medicine.","from":"paper-armstrong-n-engl-j-med","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection","note":"Lehmann BD, Jovanović B, Chen X, et al. PLoS One.","from":"paper-lehmann-tnbctype-4-refinement-plos-one-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","note":"Brown CE, Alizadeh D, Starr R, et al. New England Journal of Medicine.","from":"paper-brown-n-engl-j-med","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F","note":"Shaw AT, Friboulet L, Leshchiner I, et al. New England Journal of Medicine.","from":"paper-shaw-alk-l1198f-resensitisation-nejm-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","note":"Emile JF, Abla O, Fraitag S, et al. Blood.","from":"paper-emile-revised-classification-of-histiocytoses-blood-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","note":"Hortobagyi GN, Stemmer SM, Burris HA, et al. New England Journal of Medicine.","from":"paper-monaleesa-2-n-engl-j-med-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"RTOG 9802: radiation plus procarbazine, lomustine and vincristine in high-risk low-grade glioma","note":"Buckner JC, Shaw EG, Pugh SL, et al. New England Journal of Medicine.","from":"paper-rtog-9802-buckner-nejm-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Salmonella enterica serovar Typhi and gallbladder cancer: a case-control study and meta-analysis","note":"Koshiol J, Wozniak A, Cook P, et al. Cancer Medicine.","from":"paper-koshiol-salmonella-typhi-gallbladder-cancer-cancer-med-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Siegel 2016: Cancer statistics, 2016","note":"Siegel RL, Miller KD, Jemal A. CA: A Cancer Journal for Clinicians.","from":"paper-siegel-cancer-statistics-2016-cacancer-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving...","note":"Morrow M, Van Zee KJ, Solin LJ, et al. Journal of Clinical Oncology.","from":"paper-morrow-j-clin-oncol","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer","note":"Domingo E, Freeman-Mills L, Rayner E, et al. Lancet Gastroenterology and Hepatology.","from":"paper-domingo-somatic-pole-proofreading-colorectal-lancet-gastro-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"STOpCaP: docetaxel or bisphosphonates added to standard of care in hormone-sensitive prostate cancer, a systematic review and meta-analysis","note":"Vale CL, Burdett S, Rydzewska LHM, et al. The Lancet Oncology.","from":"paper-vale-stopcap-docetaxel-bisphosphonates-lancet-oncol-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Substantial interindividual and limited intraindividual genomic diversity among tumours from men with metastatic prostate cancer","note":"Kumar A, Coleman I, Morrissey C, et al. Nature Medicine.","from":"paper-kumar-interindividual-genomic-diversity-metastatic-prostate-nat-med-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Targeting metastasis","note":"Steeg PS. Nature Reviews Cancer.","from":"paper-steeg-nat-rev-cancer","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","note":"Baumert BG, Hegi ME, van den Bent MJ, et al. The Lancet Oncology.","from":"paper-baumert-lancet-oncol","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"The biology and function of fibroblasts in cancer","note":"Kalluri R. Nature Reviews Cancer.","from":"paper-kalluri-nat-rev-cancer","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"The Emerging Hallmarks of Cancer Metabolism","note":"Pavlova NN, Thompson CB. Cell metabolism.","from":"paper-pavlova-cell-metab","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"The multifaceted roles of fatty acid synthesis in cancer","note":"Röhrig F, Schulze A. Nature Reviews Cancer.","from":"paper-rohrig-nat-rev-cancer","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"The risk of malignancy in ultrasound detected gallbladder polyps: A systematic review","note":"Elmasry M, Lindop D, Dunne DF, et al. International Journal of Surgery.","from":"paper-elmasry-gallbladder-polyp-malignancy-systematic-review-int-j-surg-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Thyroid cancer","note":"Cabanillas ME, McFadden DG, Durante C. The Lancet.","from":"paper-cabanillas-lancet","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Trabectedin versus dacarbazine for metastatic liposarcoma or leiomyosarcoma after anthracycline failure","note":"Demetri GD, von Mehren M, Jones RL, et al. Journal of Clinical Oncology.","from":"paper-trabectedin-vs-dacarbazine-demetri-jco-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3","note":"Scher HI, Morris MJ, Stadler WM, et al. Journal of Clinical Oncology.","from":"paper-scher-j-clin-oncol","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received","note":"Schnipper LE, Davidson NE, Wollins DS, et al. Journal of Clinical Oncology.","from":"paper-schnipper-j-clin-oncol","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Use of genetically encoded, light-gated ion translocators to control tumorigenesis","note":"Chernet BT, Adams DS, Lobikin M, et al. Oncotarget.","from":"paper-chernet-oncotarget","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (TARPSWG)","note":"Gronchi A, Strauss DC, Miceli R, et al. Annals of Surgery.","from":"paper-tarpswg-retroperitoneal-sarcoma-gronchi-ann-surg-2016","refs":[]},{"group":"paper","date":"2016","precision":"year","title":"Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer","note":"Roberts NJ, Norris AL, Petersen GM, et al. Cancer Discovery.","from":"paper-roberts-familial-pancreatic-whole-genome-cancer-discov-2016","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"[18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results","note":"Radiation Oncology","from":"paola-anna-erba","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer (ProtecT)","note":"NEJM","from":"freddie-hamdy","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"2-Methoxyestradiol inhibits the proliferation and migration and reduces the radioresistance of nasopharyngeal carcinoma CNE-2 stem cells via NF-κB/HIF-1 signali...","note":"Oncology Reports","from":"wang-ying","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer","note":"Journal of Nuclear Medicine","from":"clemens-kratochwil","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prost...","note":"European Urology","from":"peter-bartenstein","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer...","note":"Annals of Oncology","from":"anthony-goncalves","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"A Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy Agents","note":"Case Reports in Oncological Medicine","from":"dearbhaile-collins","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"A Smart Photosensitizer–Manganese Dioxide Nanosystem for Enhanced Photodynamic Therapy by Reducing Glutathione Levels in Cancer Cells","note":"Angewandte Chemie International Edition","from":"tan-weihong","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial","note":"Lancet Oncology","from":"brian-rini","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma","note":"New England Journal of Medicine","from":"peter-johnson","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Adaptive Randomization of Neratinib in Early Breast Cancer","note":"New England Journal of Medicine","from":"laura-esserman","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer","note":"Gastroenterology","from":"jimmy-so","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Addressing the Role of Obesity in Endometrial Cancer Risk, Prevention, and Treatment","note":"Journal of Clinical Oncology","from":"karen-lu","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial","note":"Lancet Oncology","from":"rachel-kerr","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","note":"The Lancet","from":"katsuhiko-uesaka","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Adult acute lymphoblastic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","note":"Annals of Oncology","from":"nicola-gokbuget","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Advanced MRI increases the diagnostic accuracy of recurrent glioblastoma: Single institution thresholds and validation of MR spectroscopy and diffusion weighted...","note":"NeuroImage: Clinical","from":"tomas-kazda","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, rando...","note":"The Lancet Oncology","from":"lu-shun","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology","note":"Journal of Oncology Practice","from":"robin-zon","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3β/Foxp3 Axis","note":"Journal of Biological Chemistry","from":"xia-jiahong","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"An update on clinical oncology for the non-oncologist","note":"Einstein (São Paulo)","from":"kaliks-rafael","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study","note":"Endocrine-Related Cancer","from":"martyn-caplin","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","note":"JAMA Oncology","from":"howard-scher","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy (IMv...","note":"Lancet","from":"jonathan-rosenberg","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma (JAVELIN Merkel 200)","note":"Lancet Oncology","from":"sandra-dangelo","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint...","note":"The Lancet Oncology","from":"magdolna-dank","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From...","note":"Journal of Clinical Oncology","from":"ralf-c-bargou","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Bladder cancer","note":"Lancet","from":"ashish-kamat","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study","note":"The Lancet Haematology","from":"norbert-vey","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Carcinogenic human papillomavirus infection","note":"Nature Reviews Disease Primers","from":"mark-schiffman","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer","note":"BMC Cancer","from":"mark-burkard","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Changing Patterns of lung, liver, and head and neck non-AIDS-defining cancers relative to HIV status in Tanzania between 2002-2014","note":"Infectious Agents and Cancer","from":"diwani-msemo","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisa...","note":"Lancet Haematology","from":"andres-ferreri","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Cholesterol Sulfonation Enzyme, SULT2B1b, Modulates AR and Cell Growth Properties in Prostate Cancer","note":"Molecular Cancer Research","from":"andrew-mesecar","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal","note":"Nat Cell Biol","from":"markus-g-manz","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Clinical Characteristics of Primary Vitreoretinal Lymphoma in an Indian Population","note":"Ocular Immunology and Inflammation","from":"vivek-lal","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative Disorde...","note":"American Society of Clinical Oncology Educational Book","from":"lim-soon-thye","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Current targeted therapies in the treatment of advanced colorectal cancer: a review","note":"Therapeutic Advances in Medical Oncology","from":"john-kennedy","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial","note":"The Lancet Oncology","from":"david-planchard","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","note":"The Lancet Oncology","from":"david-planchard","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS)","note":"Lancet","from":"sagar-lonial","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma (POLLUX)","note":"NEJM","from":"meletios-dimopoulos","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter...","note":"Annals of Surgery","from":"han-kwang-yang","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","note":"Annals of the Rheumatic Diseases","from":"chak-sing-lau","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","note":"JCO","from":"ashish-kamat","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer","note":"JAMA Oncology","from":"mariana-chavez-macgregor","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression","note":"Cancer Cell","from":"lars-zender","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia","note":"Blood","from":"rachel-rau","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers","note":"British Journal of Cancer","from":"shin-sang-joon","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP)","note":"Clinical Cancer Research","from":"silvia-stacchiotti","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients","note":"Anticancer Research","from":"igor-kiss","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer","note":"Clinical Cancer Research","from":"justin-gainor","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Epidemiology of cancers in Lahore, Pakistan, 2010–2012: a cross-sectional study","note":"BMJ Open","from":"faisal-sultan","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","note":"Annals of Oncology","from":"eric-van-cutsem","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4)","note":"Lancet","from":"james-yao","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcin...","note":"PLOS Medicine","from":"james-brenton","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Extending aromatase-inhibitor adjuvant therapy to 10 years (MA.17R)","note":"NEJM","from":"parulekar-wendy","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Features of electrocoagulation syndrome after endoscopic submucosal dissection for colorectal neoplasm","note":"Journal of Gastroenterology and Hepatology","from":"nariaki-matsuura","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"First clinical application of a prompt gamma based in vivo proton range verification system","note":"Radiotherapy and Oncology","from":"michael-baumann","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic...","note":"Lancet Oncology","from":"barbara-eichhorst","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","note":"Blood","from":"emil-freireich","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed...","note":"Lancet Oncology","from":"massimo-cristofanilli","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Hepatocellular carcinoma","note":"Nature Reviews Disease Primers","from":"josep-llovet","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review","note":"Cancer","from":"ali-taher","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective","note":"Gastroenterology Research and Practice","from":"faisal-sultan","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"HERACLES: trastuzumab and lapatinib in HER2-amplified, KRAS wild-type metastatic colorectal cancer","note":"The Lancet Oncology","from":"andrea-sartore-bianchi","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial","note":"Lancet Haematology","from":"benjamin-kasenda","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"High-fat diet enhances stemness and tumorigenicity of intestinal progenitors","note":"Nature","from":"semir-beyaz","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Identification of a rectal subregion highly predictive of rectal bleeding in prostate cancer IMRT","note":"Radiotherapy and Oncology","from":"renaud-de-crevoisier","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma","note":"Nature","from":"maike-sander","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Immuno-PET of HER2-positive breast cancer with 89Zr-trastuzumab: a first-in-human study","note":"Journal of Nuclear Medicine","from":"jason-lewis","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India","note":"Lancet Oncology","from":"sankaranarayanan-rengaswamy","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Impact of primary (1º) tumor location on overall survival and progression-free survival in patients with metastatic colorectal cancer: analysis of CALGB/SWOG 80...","note":"JCO","from":"heinz-josef-lenz","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Implementation Science for Global Oncology: The Imperative to Evaluate the Safety and Efficacy of Cancer Care Delivery","note":"Journal of Clinical Oncology","from":"nadine-karema","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Increase of prevalence of craniosynostosis","note":"Journal of Cranio-Maxillofacial Surgery","from":"r-r-w-j-van-der-hulst","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Individualized adaptive stereotactic body radiotherapy for liver cancer","note":"Journal of Clinical Oncology","from":"theodore-lawrence","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Infections with multiple high‐risk HPV types are associated with high‐grade and persistent low‐grade intraepithelial lesions of the cervix","note":"Cancer Cytopathology","from":"victor-piana-de-andrade","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models","note":"Nature Medicine","from":"reuben-shaw","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","note":"New England Journal of Medicine","from":"hagop-kantarjian","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia (INO-VATE)","note":"NEJM","from":"elias-jabbour","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"L1CAM: amending the “low-risk” category in endometrial carcinoma","note":"Journal of Cancer Research and Clinical Oncology","from":"sara-brucker","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Landscape of somatic mutations in 560 breast cancer whole-genome sequences","note":"Nature","from":"michael-stratton","refs":["serena-nik-zainal"]},{"group":"person-paper","date":"2016","precision":"year","title":"Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up","note":"Breast Cancer Research and Treatment","from":"david-fennelly","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, cont...","note":"The Lancet Oncology","from":"jesus-san-miguel","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regim...","note":"Clinical Cancer Research","from":"inge-marie-svane","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Mechanisms and consequences of cancer genome instability: lessons from genome sequencing studies","note":"Annual Review of Pathology","from":"alan-dandrea","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment","note":"Hematology","from":"christiane-pott","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming","note":"Cancer Cell","from":"dario-altieri","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study","note":"˜The œLancet. Gastroenterology & hepatology","from":"lukas-b-been","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","note":"Blood","from":"brian-huntly","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intra...","note":"Journal of Clinical Oncology","from":"theodore-hong","refs":["kenneth-tanabe"]},{"group":"person-paper","date":"2016","precision":"year","title":"Neutralization of tumor acidity improves antitumor responses to immunotherapy","note":"Cancer Research","from":"shari-pilon-thomas","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer (NOVA)","note":"NEJM","from":"mansoor-raza-mirza","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial","note":"The Lancet Oncology","from":"filippo-de-braud","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","note":"Lancet","from":"usha-menon","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Palbociclib and letrozole in advanced breast cancer (PALOMA-2)","note":"NEJM","from":"richard-finn","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion","note":"Nature","from":"costas-lyssiotis","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Particle therapy at the 'tipping point': an introduction to the Red Journal's special edition","note":"International Journal of Radiation Oncology, Biology, Physics","from":"anthony-zietman","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","note":"New England Journal of Medicine","from":"jenny-donovan","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients","note":"Scientific Reports","from":"kim-hye-ryun","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Pediatric cancer outcomes and socioeconomic status: population-based studies","note":"Cancer","from":"sumit-gupta","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer (KEYNOTE-024)","note":"NEJM","from":"martin-reck","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010)","note":"Lancet","from":"roy-herbst","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"PET-CT surveillance versus neck dissection in advanced head and neck cancer (PET-NECK)","note":"NEJM","from":"hisham-mehanna","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia","note":"Haematologica","from":"richard-van-etten","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","note":"Blood","from":"stephen-forman","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial","note":"JAMA Internal Medicine","from":"michael-bretthauer","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","note":"Haematologica","from":"jurgen-kuball","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer","note":"Annals of Oncology","from":"ananya-choudhury","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research","note":"Acta Oncol","from":"ernst-j-kuipers","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Prospective study of the pattern of lymphatic metastasis in relation to the submandibular gland in patients with carcinoma of the oral cavity","note":"Head & Neck","from":"chaturvedi-pankaj","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Proteomic and phosphoproteomic analyses of EGFR-mutant lung cancer","note":"Molecular Cancer Therapeutics","from":"eric-haura","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Quality of life in patients with a permanent stoma after rectal cancer surgery","note":"Quality of Life Research","from":"pia-nasvall","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Radiation oncology in the era of precision medicine","note":"Nature Reviews Cancer","from":"michael-baumann","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Relevance of randomised controlled trials in oncology","note":"Lancet Oncology","from":"ian-tannock","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer (MONALEESA-2)","note":"NEJM","from":"gabriel-hortobagyi","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia","note":"New England Journal of Medicine","from":"norbert-vey","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme (Biomarkers France)","note":"Lancet","from":"fabrice-barlesi","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I","note":"Gynecologic Oncology","from":"ate-van-der-zee","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Serum bile acids and GLP-1 decrease following telemetric induced weight loss: results of a randomized controlled trial","note":"Sci Rep","from":"nikolai-goncharenko","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Steady-state kinetic studies reveal that the anti-cancer target Ubiquitin-Specific Protease 17 (USP17) is a highly efficient deubiquitinating enzyme","note":"Archives of Biochemistry and Biophysics","from":"andrew-mesecar","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors","note":"Hematology/Oncology Clinics of North America","from":"emily-bergsland","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"T-cell transfer therapy targeting mutant KRAS in cancer","note":"New England Journal of Medicine","from":"steven-rosenberg","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","note":"Journal of Clinical Oncology","from":"igor-puzanov","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Targeted vaccination against human α-lactalbumin for immunotherapy and primary immunoprevention of triple negative breast cancer","note":"Cancers","from":"vincent-tuohy","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type","note":"Int J Mol Sci","from":"yacine-merrouche","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Teenagers and young adults with cancer in Europe: from national programmes to a European integrated coordinated project","note":"Eur J Cancer Care (Engl)","from":"assia-konsoulova","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"The genetic architecture of type 2 diabetes","note":"Nature","from":"nikhil-tandon","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"The Interdisciplinary Management of Brain Metastases","note":"Deutsches Ärzteblatt international","from":"kirsten-schmieder","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"The transcriptome of lung tumor-infiltrating dendritic cells reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outc...","note":"OncoImmunology","from":"karim-vermaelen","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer","note":"Health Technology Assessment","from":"john-field","refs":["david-baldwin"]},{"group":"person-paper","date":"2016","precision":"year","title":"Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment: counteracting off-tumor toxicities for safe CAR T cell therapy","note":"Annual Review of Pharmacology and Toxicology","from":"zelig-eshhar","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Tumor-induced osteomalacia caused by a massive phosphaturic mesenchymal tumor of the acetabulum: A case report","note":"Modern Rheumatology","from":"yasuharu-nakashima","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"UCP2 regulates energy metabolism and differentiation potential of human pluripotent stem cells","note":"EMBO Journal","from":"michael-teitell","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"Whole Genome Sequencing Expands Diagnostic Utility and Improves Clinical Management in Pediatric Medicine","note":"npj Genomic Medicine","from":"ronald-cohn","refs":[]},{"group":"person-paper","date":"2016","precision":"year","title":"YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK–STAT3 Signaling","note":"Gastroenterology","from":"axel-behrens","refs":[]},{"group":"technology","date":"2016","precision":"year","title":"Allogeneic cell banks: one donor, hundreds of doses","note":"First use in humans or first approval, as the technology record states it.","from":"allogeneic-cell-banks","refs":[]},{"group":"technology","date":"2016","precision":"year","title":"BCL-2 inhibitors","note":"First use in humans or first approval, as the technology record states it.","from":"bcl2-inhibitors","refs":[]},{"group":"technology","date":"2016","precision":"year","title":"Electronic patient-reported outcome (ePRO) symptom monitoring","note":"First use in humans or first approval, as the technology record states it.","from":"epro-symptom-monitoring","refs":[]},{"group":"technology","date":"2016","precision":"year","title":"PET-adapted (response-adapted) therapy","note":"First use in humans or first approval, as the technology record states it.","from":"pet-adapted-therapy","refs":[]},{"group":"technology","date":"2016","precision":"year","title":"Somatostatin receptor PET (68Ga/64Cu-DOTATATE)","note":"First use in humans or first approval, as the technology record states it.","from":"sstr-pet","refs":[]},{"group":"technology","date":"2016","precision":"year","title":"Tandem autologous transplant","note":"First use in humans or first approval, as the technology record states it.","from":"tandem-transplant","refs":[]},{"group":"technology","date":"2016","precision":"year","title":"Transcranial focused ultrasound systems (Exablate Neuro, SonoCloud)","note":"First use in humans or first approval, as the technology record states it.","from":"transcranial-focused-ultrasound-systems","refs":[]},{"group":"trial","date":"2016","precision":"year","title":"10TASQ10 reported","note":"Median radiographic progression-free survival 7.0 against 4.4 months (hazard ratio 0.64, 95 percent confidence interval 0.54 to 0.75, p<0.001) but overall survival 21.3 against 24...","from":"tasquinimod-10tasq10","refs":["prostate","prostate-mcrpc","tasquinimod"]},{"group":"trial","date":"2016","precision":"year","title":"A Safety and Efficacy Study of Eltrombopag in Subjects With AML reported","from":"nct01890746","refs":["leukaemia","daunorubicin","cytarabine","eltrombopag"]},{"group":"trial","date":"2016","precision":"year","title":"AALL0232 reported","note":"Five-year event-free survival 79.6 percent with high-dose methotrexate against 75.2 percent with Capizzi methotrexate; dexamethasone benefited children aged 1 to 9 (five-year event...","from":"aall0232","refs":["all-paediatric-high-risk","all-leukemia","leukaemia","methotrexate"]},{"group":"trial","date":"2016","precision":"year","title":"ACT IV reported","note":"OS 20.1 vs 20.0 months; no benefit.","from":"act-iv","refs":["glioblastoma","rindopepimut"]},{"group":"trial","date":"2016","precision":"year","title":"Alliance N0574 (NCCTG N0574) reported","note":"Cognitive deterioration at 3 months 63.5% (SRS alone) vs 91.7% (SRS plus WBRT); no survival difference.","from":"alliance-n0574","refs":["brain-tumours","metastatic-cancer","secondary-brain-tumours"]},{"group":"trial","date":"2016","precision":"year","title":"BMT CTN 0803 reported","note":"One-year overall survival 87.3 percent and two-year overall survival 82 percent after autologous transplant, with two-year progression-free survival 79.8 percent and one-year trans...","from":"bmt-ctn-0803","refs":["hiv-associated-lymphoma","non-hodgkin-lymphoma","hodgkin-lymphoma","carmustine"]},{"group":"trial","date":"2016","precision":"year","title":"CheckMate 141 reported","note":"OS 7.5 vs 5.1 months; HR 0.70.","from":"checkmate-141","refs":["head-and-neck","oropharyngeal-cancer","oral-cavity-cancer","recurrent-metastatic-hnscc"]},{"group":"trial","date":"2016","precision":"year","title":"CheckMate 205 reported","note":"ORR 69%.","from":"checkmate-205","refs":["hodgkin-lymphoma","relapsed-refractory-hodgkin-lymphoma","nivolumab"]},{"group":"trial","date":"2016","precision":"year","title":"Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer reported","from":"nct00024167","refs":["prostate","docetaxel","doxorubicin","estramustine"]},{"group":"trial","date":"2016","precision":"year","title":"CHHiP reported","note":"5-year biochemical or clinical failure-free survival 90.6% (60 Gy in 20) vs 88.3% (74 Gy in 37), non-inferior.","from":"chhip","refs":["prostate","prostate-intermediate-risk","prostate-low-risk"]},{"group":"trial","date":"2016","precision":"year","title":"Childhood Cancer Survivor Study (CCSS) reported","note":"15-year all-cause mortality among five-year survivors fell from 12.4% (early 1970s) to 6.0% (1990s) as treatment exposures were reduced.","from":"ccss","refs":["all-leukemia","hodgkin-lymphoma","medulloblastoma","wilms-tumor"]},{"group":"trial","date":"2016","precision":"year","title":"COG ANBL0532 reported","note":"3-year EFS 61.6% vs 48.4%.","from":"anbl0532","refs":["neuroblastoma","neuroblastoma-high-risk"]},{"group":"trial","date":"2016","precision":"year","title":"COMET-1 reported","note":"Median overall survival 11.0 against 9.8 months (hazard ratio 0.90, 95 percent confidence interval 0.76 to 1.06, p=0.213): not met.","from":"comet-1","refs":["prostate","prostate-mcrpc","cabozantinib","prednisone"]},{"group":"trial","date":"2016","precision":"year","title":"Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma reported","from":"nct02739594","refs":["multiple-myeloma","ibandronic-acid","zoledronic-acid"]},{"group":"trial","date":"2016","precision":"year","title":"EORTC 22033-26033 reported","note":"Median progression-free survival 46 (radiotherapy) vs 39 months (temozolomide), no significant difference.","from":"eortc-22033","refs":["glioblastoma","brain-tumours","idh-mutant-astrocytoma","oligodendroglioma"]},{"group":"trial","date":"2016","precision":"year","title":"EORTC 22991 reported","note":"Six months of androgen suppression added to radiotherapy improved biochemical disease-free survival (hazard ratio 0.52, 95 percent confidence interval 0.41 to 0.66) and clinical pr...","from":"eortc-22991","refs":["prostate","prostate-intermediate-risk","prostate-high-risk"]},{"group":"trial","date":"2016","precision":"year","title":"EURAMOS-1 reported","note":"Poor responders: EFS HR 0.98 for MAPIE vs MAP, more toxicity. Good responders: no EFS benefit from interferon.","from":"euramos-1","refs":["osteosarcoma","methotrexate","doxorubicin","cisplatin"]},{"group":"trial","date":"2016","precision":"year","title":"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic L...","from":"nct00254163","refs":["cll","fludarabine","cyclophosphamide","rituximab"]},{"group":"trial","date":"2016","precision":"year","title":"HERACLES reported","note":"Trastuzumab plus lapatinib produced objective responses in roughly a third of refractory HER2-amplified colorectal cancers.","from":"heracles","refs":["her2-amplified-colorectal","colorectal","trastuzumab","lapatinib"]},{"group":"trial","date":"2016","precision":"year","title":"I-SPY 2 reported","note":"Multiple graduations (veliparib-carboplatin, neratinib, pembrolizumab, MK-2206, T-DM1 plus pertuzumab, durvalumab plus olaparib, cemiplimab plus fianlimab); pembrolizumab's graduat...","from":"i-spy-2","refs":["breast-cancer","tnbc","breast-her2-positive","breast-hr-positive"]},{"group":"trial","date":"2016","precision":"year","title":"IELSG32 reported","note":"Complete remission 49 percent with MATRix (methotrexate, cytarabine, thiotepa, rituximab) against 23 percent with methotrexate-cytarabine alone; two-year failure-free survival 76 p...","from":"ielsg32","refs":["primary-cns-lymphoma","non-hodgkin-lymphoma","brain-tumours","methotrexate"]},{"group":"trial","date":"2016","precision":"year","title":"IMPRESS (algenpantucel-L) reported","note":"No overall survival benefit.","from":"impress-trial","refs":["pancreatic","algenpantucel-l","gemcitabine"]},{"group":"trial","date":"2016","precision":"year","title":"INO-VATE ALL reported","note":"CR/CRi 80.7% vs 29.4%; OS 7.7 vs 6.7 months.","from":"ino-vate","refs":["all-leukemia","inotuzumab-ozogamicin"]},{"group":"trial","date":"2016","precision":"year","title":"JASPAC 01 reported","note":"Five-year overall survival 44.1 percent with adjuvant S-1 against 24.4 percent with gemcitabine (hazard ratio 0.57, 95 percent confidence interval 0.44 to 0.72; p below 0.0001).","from":"jaspac-01","refs":["pancreatic","resectable-pdac","tegafur-gimeracil-oteracil","gemcitabine"]},{"group":"trial","date":"2016","precision":"year","title":"JAVELIN Merkel 200 reported","note":"Objective response 31.8% after chemotherapy (part A) and 39.7% first line (part B).","from":"javelin-merkel-200","refs":["merkel-cell-carcinoma","skin-cancer","avelumab"]},{"group":"trial","date":"2016","precision":"year","title":"KEYNOTE-010 reported","note":"Median overall survival 10.4 months (pembrolizumab 2 mg/kg) and 12.7 months (10 mg/kg) against 8.5 months with docetaxel; hazard ratios 0.71 and 0.61.","from":"keynote-010","refs":["nsclc","pdl1-high-nsclc","pembrolizumab","docetaxel"]},{"group":"trial","date":"2016","precision":"year","title":"KEYNOTE-017 (Cancer Immunotherapy Trials Network 09) reported","note":"Objective response 56%, durable in most responders; similar in virus-positive and virus-negative tumours.","from":"keynote-017","refs":["merkel-cell-carcinoma","skin-cancer","pembrolizumab"]},{"group":"trial","date":"2016","precision":"year","title":"KEYNOTE-024 & KEYNOTE-189 reported","note":"5-year OS 31.9% vs 16.3% (024); 19.4% vs 11.3% (189).","from":"keynote-024-189","refs":["nsclc","pdl1-high-nsclc","pembrolizumab"]},{"group":"trial","date":"2016","precision":"year","title":"LAP07 reported","note":"Median overall survival 15.2 months with chemoradiotherapy against 16.5 months with chemotherapy alone (hazard ratio 1.03, p 0.83); local progression 32 against 46 percent; erlotin...","from":"lap07","refs":["locally-advanced-pdac","pancreatic","gemcitabine","erlotinib"]},{"group":"trial","date":"2016","precision":"year","title":"MAPS reported","note":"OS 18.8 vs 16.1 months, HR 0.77.","from":"maps","refs":["mesothelioma","pemetrexed"]},{"group":"trial","date":"2016","precision":"year","title":"MINDACT reported","note":"5-year distant metastasis-free survival 94.7% without chemotherapy in clinical-high, genomic-low risk women.","from":"mindact","refs":["breast-hr-positive","hr-positive-early-high-risk","mammaprint"]},{"group":"trial","date":"2016","precision":"year","title":"MONALEESA-2 reported","note":"OS 63.9 vs 51.4 months, HR 0.76.","from":"monaleesa-2","refs":["breast-hr-positive","ribociclib"]},{"group":"trial","date":"2016","precision":"year","title":"NAPOLI-1 reported","note":"Median overall survival 6.1 months with nanoliposomal irinotecan plus fluorouracil and folinic acid against 4.2 months with fluorouracil and folinic acid (hazard ratio 0.67, 95 per...","from":"napoli-1","refs":["pancreatic","metastatic-pdac","liposomal-irinotecan","fluorouracil"]},{"group":"trial","date":"2016","precision":"year","title":"OAK reported","note":"Median overall survival 13.8 against 9.6 months (hazard ratio 0.73), in both the intention-to-treat and PD-L1-expressing populations.","from":"oak","refs":["nsclc","lung-squamous-cell-carcinoma","lung-adenocarcinoma","atezolizumab"]},{"group":"trial","date":"2016","precision":"year","title":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor re...","from":"nct00569127","refs":["rectal-cancer","colon-cancer","bevacizumab-glioma"]},{"group":"trial","date":"2016","precision":"year","title":"PALOMA-2 reported","note":"PFS HR 0.56; OS HR 0.96 (NS).","from":"paloma-2","refs":["breast-hr-positive","palbociclib"]},{"group":"trial","date":"2016","precision":"year","title":"PhII ICb With/Without Erbitux in MBC Pts reported","from":"nct00248287","refs":["metastatic-cancer","carboplatin","cetuximab"]},{"group":"trial","date":"2016","precision":"year","title":"ProtecT reported","note":"15-year prostate-cancer mortality 3.1% (monitoring), 2.2% (surgery), 2.9% (radiotherapy); no significant difference.","from":"protect","refs":["prostate","prostate-low-risk","prostate-intermediate-risk"]},{"group":"trial","date":"2016","precision":"year","title":"QUARTZ reported","note":"Quality-adjusted life-years 46.4 vs 41.7 days; overall survival 9.2 vs 8.5 weeks; no meaningful benefit from whole-brain radiotherapy.","from":"quartz","refs":["nsclc","brain-tumours","secondary-brain-tumours","dexamethasone"]},{"group":"trial","date":"2016","precision":"year","title":"RATHL reported","note":"3-year PFS 85.7% (ABVD) vs 84.4% (AVD); bleomycin safely omitted.","from":"rathl","refs":["hodgkin-lymphoma","advanced-stage-classical-hodgkin-lymphoma","bleomycin"]},{"group":"trial","date":"2016","precision":"year","title":"ROMANA 1 and ROMANA 2 reported","note":"Lean body mass increased (about +1 to +1.5 kg vs placebo); handgrip strength unchanged.","from":"romana-1-2","refs":["nsclc"]},{"group":"trial","date":"2016","precision":"year","title":"RTOG 0415 reported","note":"Five-year disease-free survival 86.3 percent with 70 Gy in 28 fractions against 85.3 percent with 73.8 Gy in 41 fractions (hazard ratio 0.85, 95 percent confidence interval 0.64 to...","from":"rtog-0415","refs":["prostate","prostate-low-risk"]},{"group":"trial","date":"2016","precision":"year","title":"STAMPEDE reported","note":"Abiraterone + ADT: OS HR 0.63 in mHSPC; docetaxel + ADT: OS HR 0.78. Prostate radiotherapy improved survival in low-volume metastatic disease; abiraterone improved survival in high...","from":"stampede","refs":["prostate","prostate-mhspc","prostate-high-risk","abiraterone"]},{"group":"trial","date":"2016","precision":"year","title":"Study 2005-01 reported","note":"Day-100 survival 38.2% with defibrotide against 25% in historical controls (propensity-adjusted difference 23%, P = .0109); complete response by day 100 25.5% against 12.5%.","from":"study-2005-01","refs":["defibrotide"]},{"group":"trial","date":"2016","precision":"year","title":"Targeted axillary dissection (MD Anderson prospective study) reported","note":"Adding the clipped node to sentinel node dissection cut the false-negative rate from 10.1 to 1.4 percent (p=0.03); targeted axillary dissection gave 2.0 percent.","from":"targeted-axillary-dissection-md-anderson","refs":["breast-cancer","breast-hr-positive","breast-her2-positive","tnbc"]},{"group":"trial","date":"2016","precision":"year","title":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer reported","from":"nct00066703","refs":["breast-cancer","tamoxifen","triptorelin"]},{"group":"trial","date":"2016","precision":"year","title":"WISDOM (Women Informed to Screen Depending on Measures of Risk) reported","note":"Ongoing pragmatic trial of risk-based versus annual screening.","from":"wisdom-trial","refs":["breast-cancer"]},{"group":"guideline","date":"2016-01","precision":"month","title":"NCCN 2015-2016 updates for Melanoma","note":"1 row added. Anchored to FDA approval of nivolumab with ipilimumab, September 2015 (accelerated) and CheckMate 067 overall-survival data.","from":"melanoma","refs":["nivolumab","ipilimumab","pembrolizumab","checkmate-067"]},{"group":"regulatory","date":"2016-02-01","precision":"day","title":"Imatinib: approval (US)","note":"First US generic imatinib launched","from":"imatinib","refs":[]},{"group":"regulatory","date":"2016-02-05","precision":"day","title":"Sacituzumab govitecan: designation (US)","note":"Breakthrough Therapy designation for pretreated metastatic TNBC","from":"sacituzumab-govitecan","refs":[]},{"group":"regulatory","date":"2016-02-19","precision":"day","title":"Palbociclib: approval (US)","note":"With fulvestrant after endocrine therapy (PALOMA-3)","from":"palbociclib","refs":[]},{"group":"regulatory","date":"2016-03-04","precision":"day","title":"Ibrutinib: approval (US)","note":"First-line CLL","from":"ibrutinib","refs":[]},{"group":"regulatory","date":"2016-04-11","precision":"day","title":"Venetoclax: approval (US)","note":"CLL with 17p deletion after ≥1 therapy: first BCL-2 inhibitor","from":"venetoclax","refs":[]},{"group":"regulatory","date":"2016-05-18","precision":"day","title":"Atezolizumab: approval (US)","note":"Urothelial carcinoma after platinum (accelerated; later withdrawn)","from":"atezolizumab","refs":[]},{"group":"regulatory","date":"2016-10-18","precision":"day","title":"Atezolizumab: approval (US)","note":"NSCLC after platinum","from":"atezolizumab","refs":[]},{"group":"regulatory","date":"2016-12-19","precision":"day","title":"Rucaparib: approval (US)","note":"Accelerated approval, gBRCA/sBRCA ovarian, ≥2 prior lines","from":"rucaparib","refs":[]}]},"route":"/years/2016/","neighbours":{"year":[{"id":"2015","kind":"year","name":"2015 in oncology","route":"/years/2015/"},{"id":"2017","kind":"year","name":"2017 in oncology","route":"/years/2017/"}]}}